Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, scheduled for payment on August 11, 2023. Shareholders on record as of July 21, 2023 will be eligible to receive this payment. In 2022, the company reported revenues of approximately $3.3 billion and serves customers globally across 190 countries. As a component of the S&P 500 index, PerkinElmer remains a significant player in the life sciences and diagnostics sector, focusing on providing comprehensive solutions for disease diagnosis and drug discovery. The company is set to undergo a name change in the second quarter of 2023, reinforcing its commitment to innovation and market leadership.
PerkinElmer Inc. (NYSE: PKI) will release its first quarter 2023 financial results on May 11, 2023, before market open. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak is scheduled for 8:00 a.m. ET on the same day. The company, which is undergoing a name change in the second quarter of 2023, reported approximately $3.3 billion in revenue for 2022 and serves customers across 190 countries. As a significant player in the S&P 500 index, PerkinElmer focuses on providing innovative solutions for disease diagnosis and drug discovery.
Parkland Corporation (TSX: PKI) announced a dividend of $0.34 per share, to be paid on April 14, 2023, for shareholders of record by March 22, 2023. The ex-dividend date is set for March 21, 2023. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes, reflecting Parkland's commitment to returning value to its shareholders. The company's extensive operations span 25 countries, with approximately 4,000 retail locations across Canada, the U.S., and the Caribbean, highlighting its significant market presence and strategic growth initiatives.
PerkinElmer Inc. (NYSE: PKI) has completed the divestiture of its Applied, Food, and Enterprise Services businesses to New Mountain Capital. This strategic move allows PerkinElmer to focus on its new Life Sciences and Diagnostics company, which aims to drive scientific innovation and improve global health outcomes. The company plans to unveil a new name and ticker symbol in Q2 2023, pending shareholder approval. With approximately $3.3 billion in revenue in 2022 and operations in 190 countries, the restructured organization is poised for growth and will maintain strong commitments to service and corporate citizenship.
PerkinElmer (NYSE: PKI) announced its participation in the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 2:15 p.m. ET. Senior executives Steve Willoughby and Alan Fletcher will discuss the company's strategic priorities. Registration for the event is available here. A live audio webcast will be accessible on the company’s website, with a replay available for 30 days following the event.
PerkinElmer, a leader in the life sciences sector, has unveiled the EnVision® Nexus™ system, its most advanced multimode plate reader, at SLAS2023. This innovative platform enhances high-throughput screening (HTS) capabilities, significantly supporting drug discovery by allowing researchers to screen millions of samples with improved speed and accuracy. Additionally, PerkinElmer introduced the Zephyr® G3 NGS iQ™ workstation for automating NGS library preparation, further enhancing laboratory efficiency. With its robust portfolio and commitment to advancing scientific research, PerkinElmer aims to drive R&D productivity across various applications.
